To view this email as a web page, click here.

Study Explains the Uptick of Prostate Cancer in World Trade Center First Responders

Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.

Promising Combo for Triple-Negative Breast Cancer, but Only With a BRCA Mutation

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

IN CASE YOU MISSED IT

ASCO Updates Guidelines for Early Breast Cancer Based on TAILORx, MINDACT Trials

ASCO has updated its endorsement of a guideline regarding adjuvant systemic therapy decisions for early-stage operable breast cancer.

One FDA-approved test analyzes 324 cancer-relevant genes

FoundationOne^®CDx analyzes all recommended genomic biomarkers for solid tumors and provides direct paths to therapy for companion diagnostic indications. This one test can help guide therapy selection and clinical trial options for more patients.

Read more.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.